Cynata Therapeutics Ltd has released a press release.
Cynata to Acquire IP from Tekcyte
Filed with ASX ·
6ix hasn’t read this filing yet.
Cynata Therapeutics Limited on 6ix
Earlier from Cynata Therapeutics
- Further GvHD Clinical Data Published in Nature Medicine
- DFU Clinical Trial Enrolment Complete
- EU Approval for Phase 2 CYP-001 Trial in GvHD
- First Patient Treated in Phase 2 GvHD Trial
- Encouraging Initial Data from CYP-006TK DFU Trial
Later from Cynata Therapeutics
- Study of Cymerus MSCs in Pulmonary Fibrosis Published
- Cynata Receives $1.88m R&D Tax Incentive Refund
- Trading Halt
- Demonstrated Safety & Efficacy in DFU Clinical Trial
- Cynata secures commitments for $8.1m institutional placement
Follow Cynata Therapeutics into a list and get an email when it puts out news.
Follow Cynata Therapeutics